"cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide

Molecular Pharmacology

Volumn 59, Issue 1, 2001, Pages 54-61

  Bellamy, T C ^a   Garthwaite, J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CALCIUM; CALCIUM IONOPHORE; CYCLIC AMP; CYCLIC GMP; MILRINONE; NITRIC OXIDE; PHOSPHODIESTERASE; ROLIPRAM; SILDENAFIL; ZAPRINAST;

ANIMAL CELL; ARTICLE; ASTROCYTE; CALCIUM CELL LEVEL; CELL SUSPENSION; CEREBELLUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SECOND MESSENGER;

EID: 0035164908     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.1.54     Document Type: Article

References (43)

1. Calmodulin controls neuronal nitricoxide synthase by a dual mechanism. Activation of intra- and interdomain electron transfer
2. 2+/calmodulin-dependent cyclic GMP phosphodiesterase activity in granule neurons and astrocytes from rat cerebellum
3. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes
4. Phosphodiestorase 4 conformers: Preparation of recombinant enzymes and assay for inhibitors
5. Multiple isozymes of cyclic nucieotide phosphodiestorase
6. Cyclic nucleotide phosphodiestorases: Functional implications of multiple isoforms
7. Rapid desensitization of the nitric oxide receptor, soluble gnanylyl cyclase, underlies diversity of cellular cGMP responses
8. Another member of the cyclic nucleotide-gated channel family, expressed in testis, kidney, and heart
9. 50) of an enzymatic reaction
10. Preparation of viable astrocytes from the developing cerebellum
11. Cyclic GMP phosphcdiesterase-5: Target of sildenafil
12. Immunocytochemistry of cGMP in the cerebellum of the immature, adult, and aged rat: The involvement of nitric oxide. A micropharmacological study
13. Statistical estimations in enzyme kinetics. The integrated Michaelis equation
14. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase
15. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes beth cAMP and cGMP (PDE10A)
16. Separation of cell types from the carebellum and their properties
17. Nitric oxide signaling in the central nervous system
18. Cellular origins of cyclic GMP responses to excitatory amino acid receptor agonists in rat cerebellum in vitro
19. Analysis of a mutation in phosphodiestorase type 4 that alters both inhibitor activity and nucleotide selectivity
20. Soluble guanylate cyclase: The forgotten sibling
21. Differential distribution of mRNA encoding cAMP-specific phosphodiestorase isoforms in the rat brain
22. Widespread expression of olfactory cyclic nucleotide-gated channel genes in rat brain: Implications for neuronal signalling
23. Expression of rat cGMP-binding cGMP-specific phosphodiesterase mRNA in Purkinje cell layers during postnatal neuronal development
24. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE 3 gene family)
25. 2+
26. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition
27. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphcdiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram
28. Nitric oxide: Physiology, pathophysiology, and pharmacology
29. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells
30. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition
31. Functional receptors for neurotransmitters on astroglial cells
32. Regulation of nitric oxide-responsive recombinant soluble guanylyl cyclase by calcium
33. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum
34. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
35. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
36. Molecular characterization and in situ localization of a full-length cyclic nucleotide-gated channel in rat brain
37. Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future?
38. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds
39. Models of the diffusional spread of nitric oxide: Implications for neural nitric oxide signalling and its pharmacological properties
40. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain
41. Red-type cyclic nucleotide-gated cation channel is expressed in vascular endothelium and vascular smooth muscle cells